Table 2. BRAFV600E mutation or PD-L1 expression in PTMC patients.
| Parameters | Total (n=53) | BRAFV600E mutation | PD-L1 expression | |||||
|---|---|---|---|---|---|---|---|---|
| Positive (n=18) | Negative (n=35) | P value | Positive (n=24) | Negative (n=29) | P value | |||
| Age at diagnosis (years) | 44.8±10.6 | 49.1±11.6 | 42.6±9.4 | 0.031 | 46.2±10.6 | 43.7±10.6 | 0.394 | |
| Sex | ||||||||
| Male | 9 (17.0) | 2 (11.1) | 7 (20.0) | 0.667 | 3 (12.5) | 6 (20.7) | 0.672 | |
| Female | 44 (83.0) | 16 (88.9) | 28 (80.0) | 21 (87.5) | 23 (79.3) | |||
| Multifocality | 20 (37.7) | 5 (27.8) | 15 (42.9) | 0.283 | 10 (41.7) | 10 (34.5) | 0.591 | |
| Envelope invasion | 20 (37.7) | 8 (44.4) | 12 (34.3) | 0.470 | 9 (37.5) | 11 (37.9) | 0.974 | |
| Extraglandular invasion | 9 (17.0) | 4 (22.2) | 5 (14.3) | 0.732 | 5 (20.8) | 4 (13.8) | 0.755 | |
| Lymphatic, vascular and nerve invasion | 1 (1.9) | 0 (0) | 1 (2.9) | 1.000 | 1 (4.2) | 0 (0) | 0.453 | |
| Cervical lymph node metastasis | 26 (49.1) | 10 (55.6) | 16 (45.7) | 0.497 | 9 (37.5) | 17 (58.6) | 0.126 | |
| Concomitant HT | 7 (13.2) | 3 (16.7) | 4 (11.4) | 0.916 | 4 (16.7) | 3 (10.3) | 0.788 | |
| 131I dose (mCi) | 0 [0] | 0 [0] | 0 [0] | 0 [0] | 0 [0] | |||
| Follow-up time (months) | 135 [5.1] | 134 [5.6] | 135 [4.8] | 133 [5.1] | 135 [5.1] | |||
Normally distributed measurement data are expressed as the mean ± standard deviation, such as age at diagnosis. Skewed measurement data are expressed as the median [interquartile range], such as 131I dose and follow-up time. Categorical data are expressed as frequency (percentage of all cases) [n (%)], including sex, multifocality, envelope invasion, extraglandular invasion, lymphatic, vascular and nerve invasion, cervical lymph node metastasis, concomitant HT. PD-L1, programmed death-ligand 1; PTMC, papillary thyroid microcarcinoma; HT, Hashimoto’s thyroiditis.